Published on February 19, 2010 at 1:15 AM
Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the U.S. Patent and Trademark office has allowed for issuance a Patent on Positron’s Tech-Assist™. The Tech-Assist™, invented under the direction of John A. Zehner, a nuclear pharmacist, dramatically reduces exposure to the worker while injecting radiopharmaceuticals into patients when performing Positron Emission Tomography (PET) imaging studies. Currently utilized at several institutions to reduce or eliminate radiation exposure, the Tech-Assist™ can accept single syringes from a nuclear pharmacy or can be combined with other Positron equipment such as the Nuclear Pharm-Assist® to dispense unit doses from a vial. The Tech-Assist™ fully compliments the Attrius™, Positron’s cardiac and whole body PET scanner.
“The Tech-Assist™ is an affordable solution to reduce or eliminate exposure caused by the process of injecting PET isotopes”
“The Tech-Assist™ is an affordable solution to reduce or eliminate exposure caused by the process of injecting PET isotopes,” stated John A. Zehner, COO and Radiation Safety Officer of Positron. “Many new F-18 agents have the potential to increase exposure to the worker, reducing the exposure from a new agent will allow that agent to become widely utilized. F-18 agents are expected to significantly increase in use for multiple applications, including Cardiac and whole body bone imaging. This patent provides Positron the protection to grow this market segment and demonstrates Positron’s dedication to improving Nuclear Medicine through innovation.”
SOURCE Positron Corporation